Log In
Print this Print this

Myocet, doxorubicin

Also known as: formerly Evacet, TLC D-99

  Manage Alerts
Collapse Summary General Information
Company Teva Pharmaceutical Industries Ltd.
DescriptionLiposomal doxorubicin
Molecular Target Topoisomerase II (TOP2)
Mechanism of ActionTopoisomerase II inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationBreast cancer
Indication DetailsFirst-line treatment of HER2-positive metastatic breast cancer; Treat metastatic breast cancer; Treat metastatic HER2-overexpressing breast cancer; Treat previously untreated HER2-overexpressing locally advanced non-operable breast cancer or metastatic breast cancer
Regulatory Designation U.S. - Fast Track (First-line treatment of HER2-positive metastatic breast cancer)
PartnerSopherion Therapeutics LLC

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
Get a free BioCentury trial today